TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03460548

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remogen
Description: instil 1 drop of the product in each eye, 4 times per day

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cationorm
Description: instil 1 drop of the product in each eye, 4 times per day
Study: NCT04284566

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU + multicomponent treatment FIBROWALK
Description: Group treatment protocol of 12 weekly 120 minute sessions. All sessions include the following ingredients (approx. in the same order):~* Pain neuroscience education (30 min.)~* Cognitive restructuring (30min.)~* Mindfulness techniques (30 min.)~* Physical exercise(30 min.)~* Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with fibromyalgia.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Treatment-as-Usual (TAU) consisted of prescribing drugs adapted to the symptomatic profile of each patient. The patients were instructed to continue their baseline medical treatment with no change throughout the 3-month period. In Spain, some counselling about aerobic exercise adjusted to patients' physical limitations is usually provided by first-line clinicians and specialists, but pharmacotherapy it's still the dominant treatment option.
Study: NCT02917720

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TKI discontinuation
Description: 2nd or 3rd TKI stop after pre-treatment with nilotinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nilotinib
Description: Pre-treatment with nilotinib 300 mg/bid for 2 years
Study: NCT01048866

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Sugar-based lozenge flavoured to match the active treatment lozenge. Instructions were to suck one lozenge until gone, every 3-6 hours as needed for sore throat pain. The participant took nothing by mouth except study medication during the first two hours while at the site. For each re-dosing during the remaining time in the study, alcohol and caffeine-containing beverages (e.g., coffee, tea, hot chocolate, caffeinated soft drinks) were not consumed within 1 hour before the participant used a study medication lozenge.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flurbiprofen
Description: Sugar-based, flavoured flurbiprofen 8.75 mg lozenge. Instructions were to suck one lozenge until gone, every 3-6 hours as needed for pain. The participant took nothing by mouth except study medication during the first two hours while at the site. For each re-dosing during the remaining time in the study, alcohol and caffeine-containing beverages (e.g., coffee, tea, hot chocolate, caffeinated soft drinks) were not consumed within 1 hour before the participant used a study medication lozenge.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen 650mg
Description: Rescue medication to be taken as needed. Rescue medication was not blinded.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: acetaminophen 650mg
Description: Rescue medication to be taken as needed. Rescue medication was not blinded.
Study: NCT00841399

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E75 + GM-CSF vaccine
Description: Dose escalation scheme involving three patients each receiving injection of 100, 500, or 1,000 mcg E75 + GM-CSF monthly for 6 months. HLA-A2 and HLA-A3 status determined. HLA-A2+ and HLA-A3+ patients receive the vaccine; HLA-A2- and HLA-A3- enrolled to the control arm.
Study: NCT01077310

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in this arm will receive monthly intramuscular gluteal injections of placebo for 6 months. The 1st injection will be administered prior to release from prison or jail. Placebo will be provided by Alkermes pharmaceuticals, the manufacturer of VIVITROL. Placebo will be identical in shape and form to active drug.
Study: NCT02306148

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Foot and ankle strengthening
Description: Group will be trained during 2 months at the university by a physiotherapist and at home with a training software for foot and ankle strengthening.
Study: NCT01569061

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LCT-1000TM (Manufacturer: LiteCure)
Description: low level laser therapy (LLLT)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: LCT-1000TM (Manufacturer: LiteCure)
Description: low level laser therapy (LLLT) sham treatment
Study: NCT01038726

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Training
Description: Aerobic exercise training program designed by the Cardiac Rehabilitation department

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Training
Description: Aerobic exercise training program designed by the Cardiac Rehabilitation department

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training
Description: Based on cognitive training program Brain Fitness®

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training
Description: Based on cognitive training program Brain Fitness®

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flexibility Training
Description: Non-aerobic flexibility training program designed by the Cardiac Rehabilitation department

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Sessions
Description: DVD-based educational programs on history, art, and literature
Study: NCT04432805

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Performing of lung ultrasound
Description: Performing of lung ultrasound at bedside in labor ward or in COVID unit
Study: NCT04240093

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA) Therapy
Description: 8 sessions of behavioral activation therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Substance Abuse and Health Navigation Counseling
Description: 2 standard substance abuse and health navigation counseling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Substance Abuse and Health Navigation Counseling
Description: 2 standard substance abuse and health navigation counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medications for Opioid Use Disorder
Description: Medications for opioid use disorder (i.e., buprenorphine and methadone) as prescribed by a community provider (not provided as part of the study).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medications for Opioid Use Disorder
Description: Medications for opioid use disorder (i.e., buprenorphine and methadone) as prescribed by a community provider (not provided as part of the study).
Study: NCT00907296

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Administered by subcutaneous injection
Study: NCT02306148

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot and ankle strengthening
Description: Group will be trained during 2 months at the university by a physiotherapist and at home with a training software for foot and ankle strengthening.
Study: NCT00907296

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Administered by subcutaneous injection
Study: NCT04185792

Intervention type: DIAGNOSTIC_TEST
Intervention: NBSS, Qualiveen and SF-Qualiveen
Description: NBSS, Qualiveen and SF-Qualiveen are self-reported questionnaires.

Intervention type: DIAGNOSTIC_TEST
Intervention: NBSS, Qualiveen and SF-Qualiveen
Description: NBSS, Qualiveen and SF-Qualiveen are self-reported questionnaires.
Study: NCT00907296

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection
Study: NCT05271825

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Broadband amplification from hearing aids
Description: Amplification from 125 Hz to 10 kHz

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Band-limited amplification from hearing aids
Description: Amplification from 25 Hz to 3-4 kHz
Study: NCT04292457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Anesthesia is maintained with a continuous infusion of Propofol. Induction of anesthesia and anesthetic management are otherwise the same in both study arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Anesthesia is maintained with a continuous inhalation of Sevoflurane. Induction of anesthesia and anesthetic management are otherwise the same in both study arms.
Study: NCT01278784

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 0.05% Chitosan-N-Acetylcysteine eye drops
Description: Subjects will be randomized to receive one drop of the medical device in either the right or left eye

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 0.1% Chitosan-N-Acetylcysteine eye drops
Description: Subjects will be randomized to receive one drop of the medical device in either the right or left eye
Study: NCT02067325

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Thai massage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thai massage
Study: NCT02292615

Intervention type: OTHER
Intervention: Medical Imaging

Intervention type: OTHER
Intervention: Medical Imaging

Intervention type: OTHER
Intervention: Medical Imaging
Study: NCT02892721

Intervention type: OTHER
Group type: OTHER
Intervention: Training with feedback
Description: One-day workshop of face to face training, comprising a mixture of theory and real-world CTC cases. Radiologists will complete four interpretation assessments lasting 2 to 3 hours: one set of 10 CTC cases immediately prior to training and a further test set of 10 immediately after, with tests repeated at 6 and 12 months (using different CTC cases for each set). Radiologists will be asked to identify colorectal cancer and polyps on the scans and complete an online answer form, including questions regarding diagnostic confidence, site of abnormality and management.~The intervention group will receive online, confidential, individualised feedback after each test, which will include a case by case breakdown of their performance with explanatory answers and learning points.
Study: NCT00803972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: recombinant human hyaluronidase PH20

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: recombinant human hyaluronidase PH20

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: recombinant human hyaluronidase PH20

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: recombinant human hyaluronidase PH20

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: recombinant human hyaluronidase PH20

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: recombinant human hyaluronidase PH20

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: recombinant human hyaluronidase PH20

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: recombinant human hyaluronidase PH20

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Human Injection
Description: injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Human Injection
Description: injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Human Injection
Description: injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro Injection
Description: injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro Injection
Description: injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro Injection
Description: injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro Injection
Description: injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro Injection
Description: injection
Study: NCT04179513

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB224 10mg
Description: 10 mg, 12subjects, abdominal subcutaneous injection, the next dose group can be initiated only after the safety and tolerability are confirmed within 4 weeks after the second dosing is given.~Dosage and administration at enrollment are maintained (10\~15 mg/week), oral administration, a total of 32 doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB224 20mg
Description: 20 mg, 12subjects, abdominal subcutaneous injection, the next dose group can be initiated only after the safety and tolerability are confirmed within 4 weeks after the second dosing is given.~Dosage and administration at enrollment are maintained (10\~15 mg/week), oral administration, a total of 32 doses.
Study: NCT01683058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole IM Depot
Description: Aripiprazole IM Depot 400 mg or 300 mg
Study: NCT04042272

Intervention type: DIAGNOSTIC_TEST
Intervention: S100β, Neuron specific enolase (NSE) and Glial fibrillary acidic protein (GFAP)
Description: S100β is 10.4 kDa protein. Synthesized with end-feet processes of astrocytes in the brain S100β belongs to low molecular weight EF-hand type acidic calcium-binding protein superfamily. This protein is metabolized in the kidneys and removed with urine. It is shown that S100β does not show differences due to ethnical groups or genders and is not affected by circadian rhythm. Although S100β is also found in other tissues, it is in higher concentrations in the brain so it can be used as an early indicator for brain damage.NSE is an SSS protein which exists in neurons and neuroendocrine tissues. NSE plays a role in glycolytic route in neurons as intracytoplasmic enzyme increasing serum level in case of neuron damage. Whilst S100β is the marker of astroglia dysfunction, NSE is the marker of neuronal dysfunction. Glial fibrillary acidic protein (GFAP) is the intermediate filament cell skeleton protein found in astrocytes. It originates from the same root structure as S100β.

Intervention type: DIAGNOSTIC_TEST
Intervention: S100β, Neuron specific enolase (NSE) and Glial fibrillary acidic protein (GFAP)
Description: S100β is 10.4 kDa protein. Synthesized with end-feet processes of astrocytes in the brain S100β belongs to low molecular weight EF-hand type acidic calcium-binding protein superfamily. This protein is metabolized in the kidneys and removed with urine. It is shown that S100β does not show differences due to ethnical groups or genders and is not affected by circadian rhythm. Although S100β is also found in other tissues, it is in higher concentrations in the brain so it can be used as an early indicator for brain damage.NSE is an SSS protein which exists in neurons and neuroendocrine tissues. NSE plays a role in glycolytic route in neurons as intracytoplasmic enzyme increasing serum level in case of neuron damage. Whilst S100β is the marker of astroglia dysfunction, NSE is the marker of neuronal dysfunction. Glial fibrillary acidic protein (GFAP) is the intermediate filament cell skeleton protein found in astrocytes. It originates from the same root structure as S100β.
Study: NCT01403376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teriflunomide
Description: Film-coated tablet~Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teriflunomide
Description: Film-coated tablet~Oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon-β-1
Description: Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine
Description: Inactivated, split-virion influenza vaccine 2011-2012~One administration by intramuscular or intradermal route as per product specification

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Description: Inactivated, split-virion influenza vaccine 2011-2012~One administration by intramuscular or intradermal route as per product specification

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Description: Inactivated, split-virion influenza vaccine 2011-2012~One administration by intramuscular or intradermal route as per product specification
Study: NCT01878786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: One of the immunosuppressants currently being evaluated to replace CNIs in patients with CNI nephropathy is the mammalian Target of Rapamycin (mTOR) inhibitor, Sirolimus. Everolimus is a derivative of Sirolimus and belongs to this class of immunosuppressants, therefore, both drugs have similar side effect profile. The half-life of Everolimus is almost half of Sirolimus (Everolimus 30 hours vs Sirolimus 62 hours), which makes its dose adjustment easier although it would require more frequent dosing. In clinical trials, Everolimus has demonstrated its potential role as a safe alternative in minimizing and/or eliminating CNI such as Cyclosporin A and Tacrolimus .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: One of the immunosuppressants currently being evaluated to replace CNIs in patients with CNI nephropathy is the mammalian Target of Rapamycin (mTOR) inhibitor, Sirolimus. Everolimus is a derivative of Sirolimus and belongs to this class of immunosuppressants, therefore, both drugs have similar side effect profile. The half-life of Everolimus is almost half of Sirolimus (Everolimus 30 hours vs Sirolimus 62 hours), which makes its dose adjustment easier although it would require more frequent dosing. In clinical trials, Everolimus has demonstrated its potential role as a safe alternative in minimizing and/or eliminating CNI such as Cyclosporin A and Tacrolimus .
Study: NCT01897545

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Circumferential PV isolation
Description: The left atrium (LA) and pulmonary veins (PVs) are explored through a transeptal approach. Real-time 3D LA maps are reconstructed by using a nonfluoroscopic navigation system. The ipsilateral left and right PVs are encircled in one lesion line by circumferential PV isolation. Radiofrequency energy is delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and is reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion is ablated continuously until the local potential amplitude decreased by \>80% or RF energy deliveries exceeded 40 s. The endpoint of circumferential PV isolation is PV isolation. Additional ablation lines are created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs. After the end of the procedure the implantable loop recorder is implanted in the parasternal area of the chest.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PV isolation+renal denervation
Description: The procedure of AF ablation is the same like in the circumferential PV isolation.~After AF ablation procedure, the angiogram of both renal arteries is performed via femoral access. After that the treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done.
Study: NCT03329716

Intervention type: OTHER
Group type: OTHER
Intervention: Brace weaning
Description: For AIS patients who have been wearing Boston brace and attend clinic consultation where the decision for brace weaning is made, then weaning protocol of either arm will be prescribed

Intervention type: OTHER
Group type: OTHER
Intervention: Brace weaning
Description: For AIS patients who have been wearing Boston brace and attend clinic consultation where the decision for brace weaning is made, then weaning protocol of either arm will be prescribed
Study: NCT00680758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: * Dose Level: -3 20mg/m2/week 3-6 patients~* Dose Level: -2 20mg/m2/week 3-6 patients~* Dose Level: -1 25mg/m2/week 3-6 patients~* Dose Level: 1 25mg/m2/week 3-6 patients~* Dose Level: 2 25mg/m2/week 3-6 patients~* Dose Level: 3 25mg/m2/week 3-6 patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: * Dose Level: -3 20mg/m2/week 3-6 patients~* Dose Level: -2 20mg/m2/week 3-6 patients~* Dose Level: -1 20mg/m2/week 3-6 patients~* Dose Level: 1 20mg/m2/week 3-6 patients~* Dose Level: 2 25mg/m2/week 3-6 patients~* Dose Level: 3 30mg/m2/week 3-6 patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: * Dose Level: -3 65mg/m2/week 3-6 patients~* Dose Level: -2 70mg/m2/week 3-6 patients~* Dose Level: -1 70mg/m2/week 3-6 patients~* Dose Level: 1 80mg/m2/week 3-6 patients~* Dose Level: 2 80mg/m2/week 3-6 patients~* Dose Level: 3 80mg/m2/week 3-6 patients
Study: NCT03311984

Intervention type: DIAGNOSTIC_TEST
Intervention: anti Xa level
Description: monitoring the anti-Xa level according to LMWH emploing

Intervention type: DIAGNOSTIC_TEST
Intervention: anti Xa level
Description: monitoring the anti-Xa level according to LMWH emploing
Study: NCT03587753

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary fatty acid partitioning
Description: There is no intervention as such, just a physiological assessment of the partitioning and oxidation of two different types of dietary fatty acids

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary fatty acid partitioning
Description: There is no intervention as such, just a physiological assessment of the partitioning and oxidation of two different types of dietary fatty acids
Study: NCT01196845

Intervention type: DEVICE
Group type: OTHER
Intervention: cPAP
Description: Patients are randomised in 2 arms : cPAP or sham cPAP

Intervention type: DEVICE
Group type: OTHER
Intervention: cPAP
Description: Patients are randomised in 2 arms : cPAP or Sham cPAP

Intervention type: DEVICE
Group type: OTHER
Intervention: cPAP
Description: Patients are randomised in 2 arms : cPAP or sham cPAP

Intervention type: DEVICE
Group type: OTHER
Intervention: cPAP
Description: Patients are randomised in 2 arms : cPAP or sham cPAP